Abstract

Choice of first line treatment for patients with metastatic colorectal cancer (mCRC) is based on tumor and patient related factors and molecular information for determination of individual treatment aim and thus treatment intensity. Recent advances (e.g., extended RAS testing) enabled tailored patient assignment to the most beneficial treatment approach. Besides fluoropyrimidines, irinotecan and oxaliplatin, a broad variety of molecular targeting agents are currently available, e.g., anti-angiogenic agents (bevacizumab) and epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab) for first line treatment of mCRC. Although some combinations should be avoided (e.g., oral or bolus fluoropyrimidines, oxaliplatin and EGFR antibodies), treatment options range from single agent to highly effective four-drug regimen. Preliminary data comparing EGFR antibodies and bevacizumab, both with chemotherapy, seem to favor EGFR antibodies in RAS wildtype disease. However, choosing the most appropriate treatment approach for mCRC patients remains a complex issue, with numerous open questions.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Colorectal cancer; Metastatic; Induction chemotherapy; Epidermal growth factor receptor

INTRODUCTION

After lung (1.61 million cases) and breast cancer (1.38 million), colorectal cancer (CRC, 1.23 million) is one of the most commonly diagnosed malignancies worldwide[1]. Moreover, after lung cancer, CRC is the second most common cause of cancer deaths[2]. Around one quarter of patients with CRC present with metastatic disease at time of diagnosis (synchronous disease), and up to 40% of patients will develop metastases during the course of their disease, resulting in a relatively high overall mortality rate associated with CRC.

As a result of recent advances in the treatment of
metastatic colorectal cancer (mCRC), median overall survival (OS) can now be as long as 30 mo in selected patient groups and up to 70% of patients will receive at least two lines of treatment\(^\text{[13,17]}\). Several drugs as single agent or in various combinations are available for mCRC, including fluoropyrimidines (5FU, capecitabine), irinotecan, oxaliplatin, the vascular endothelial growth factor (VEGF) antibody bevacizumab, the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab for R\(A\S\) wildtype patients, the VEGF receptors 1 and 2 fusion protein aflibercept and the multitarget tyrosine kinase inhibitor regorafenib. Moreover, secondary resection and/or ablation e.g., by surgery or radiofrequency may contribute to long-term survival and even cure, or at least allow a relevant chemotherapy free interval\(^\text{[18]}\).

According to recent data, choice of first line treatment seems to be relevant for further course of disease, despite available efficacious second, third and if applicable fourth line regimen and the cross over use of all available drugs in later lines. The aim of this article is to review the available data on choice of first line treatment in mCRC. Pertinent data from published trials and reports and abstracts presented at selected oncology association meetings [American Society of Clinical Oncology and European Society for Medical Oncology (ESMO)/European cancer organisation] until September 2013 were reviewed.

**PROGNOSTIC FACTORS FOR PATIENT STRATIFICATION**

Prognosis of mCRC depends on several patient related (e.g., age, performance status, co-morbidity), tumour related (e.g., spread of disease, growth dynamics, symptoms, localization in particular liver and/or extrahepatic metastases), biochemical (e.g., baseline values of carcinoembryonic antigen, lactate dehydrogenase, platelets, leucocytes, haemoglobin, alkaline phosphatase, albumine) or molecular factors (e.g., R\(A\S\) or NR\(A\S\) mutations, BR\(A\F\) mutation)\(^\text{[10]}\). Whereas BR\(A\F\) mutation is associated with shorter survival, prognostic value of R\(A\S\) mutation is not clarified yet\(^\text{[11,12]}\). Some factors are combined to scores, which might be useful for stratification of patients within clinical trials and in daily clinical practise (Table 1)\(^\text{[13-18]}\). Determination of patients’ individual prognoses might be useful for choice of treatment, particularly in regard of intensity of systemic treatment and integration of local ablation into the overall therapeutic concept.

Besides the above-mentioned factors prognostic information can be derived from a broad variety of tissue or blood markers, e.g., circulating tumour cells, levels of growth factor receptor-ligands, mutations or amplifications within the relevant signalling pathways or receptors, or epigenetic alterations\(^\text{[16,17]}\). These prognostic factors might gain relevance in the future, but are currently neither broadly available nor relevant for clinical decisions\(^\text{[19]}\).

**PREDICTIVE FACTORS FOR TREATMENT EFFICACY OR TOXICITY**

Despite tremendous efforts in searching for predictive markers in mCRC, only R\(A\S\) mutation have been established, precluding treatment with EGFR antibodies. Initially R\(A\S\) mutations in exon 2 (codon 12 and 13) have been found to be predictive for non-response to cetuximab or panitumumab\(^\text{[18,19]}\). Although data are conflicting, R\(A\S\) codon G13D mutation (16% of R\(A\S\) mutated tumours) seems not to preclude efficacy of cetuximab in patients with R\(A\S\) mutations\(^\text{[20,21]}\). However, neither in the COIN trial, combining oxaliplatin with different fluoropyrimidine schedules and cetuximab, nor in the available panitumumab trials R\(A\S\) G13D mutated tumours seem to derive relevant benefit from anti-EGFR treatment\(^\text{[22-24]}\).

Recently, retrospective analyses of the PRIME study demonstrated the negative predictive value of R\(A\S\) mutation in exon 3 and 4 and NR\(A\S\) mutations in exon 2,3 and 4 for treatment with 5FU/leucovorin and oxaliplatin (FOLFFOX) and panitumumab\(^\text{[25]}\). In patients with any RAS mutational status will likely be of similar impact for cetuximab treatment\(^\text{[25]}\).

Despite the strong adverse prognostic effect of BR\(A\F\) mutation (8% of R\(A\S\) wild-type patients), the predictive value for treatment with EGFR antibodies is still unclear, with some analysis indicating a lack of benefit, particularly in advanced treatment situations\(^\text{[24,26,27]}\), whereas data from first line trials (CRYSTAL, PRIME and OPUS) show
Table 2  European Society for Medical Oncology clinical groups for first line treatment stratification\cite{10}

| ESMO group | Clinical presentation                          | Treatment aim                      | Treatment intensity |
|------------|-----------------------------------------------|------------------------------------|---------------------|
| 0          | Clearly R0-resectable liver and/or lung metastases | Decrease risk of relapse or delay relapse | FOLFOX              |
| 1          | Liver and/or lung metastases only which: Might become resectable after induction chemotherapy | Maximum tumour shrinkage | Three or four drug combination |
| 2          | Multiple metastases/sites, with: Rapid progression and/or Tumour-related symptoms/risk of rapid deterioration | Immediate clinically relevant response or at least tumour control | Three or four drug combination |
| 3          | Multiple metastases/sites without option for resection and no major symptoms or severe comorbidity | Abrogation of further progression Tumour shrinkage less relevant with Low toxicity essential | Single agent, or Doublet with low toxicity |

ESMO: European Society for Medical Oncology.

some benefit\cite{33,36}.

There is no baseline predictive marker for the available anti-angiogenic drugs e.g., bevacizumab or aflibercept. Changes in levels of angiogenic factors (e.g., basic fibroblast, placental, or hepatocyte growth factor) during treatment with bevacizumab might indicate development of resistance and predict progression\cite{29,30}. However, as recently shown in two randomized phase III trials resistance to chemotherapy occurs before resistance to bevacizumab\cite{31,32}.

Beside the prediction of treatment toxicity (diverse pyrimidine-dehydrogenase deficiency for fluoropyrimidines or uridine-glucuronosyltransferase (UGT1A1) polymorphism for irinotecan), drug efficacy (e.g., by topoisomerase-1 overexpression for irinotecan, or excision repair cross-complementing gene 1 polymorphisms for oxaliplatin) cannot be reliably predicted\cite{33,37}.

Current research focuses on distinct subsets of CRC patients defined by gene arrays, epigenetic alterations, or cancer stem cells, which might allow for a better treatment stratification\cite{38-42}. Moreover, liquid biopsies (either by analysis of circulating DNA or tumour cells) obtained during course of treatment might give insights into tumour changes and development of resistance\cite{43-46}.

**STRATIFICATION OF FIRST LINE MANAGEMENT FOR MCRC**

Decision of treatment intensity for first line treatment should be based on clinical presentation at diagnosis, considering factors like patients’ characteristics independent from the malignant disease, (if given) tumour-related symptoms, patients’ preferences, localisations of metastases, and the general treatment aim. Current ESMO guidelines stratify patients according to these factors in clinical groups with different treatment intensities (Table 2)\cite{10}.

Four groups are defined: ESMO group 0 comprising patients with clearly resectable liver metastases, group 1 with potentially resectable disease after achieving tumour response, group 2 symptomatic patients or high tumour load with risk of rapid deterioration and finally group 3 with asymptomatic, low tumour burden and severe comorbidity.

For ESMO group 0 patients with clearly R0 resectable colorectal liver metastases surgery is the treatment of choice due to the proven chance of cure, whereas the sequence and intensity of perioperative chemotherapy is controversial. Based on the current ESMO consensus these patients should be managed preferably by perioperative FOLFOX for 3 mo before and 3 mo after resection\cite{10,47,48}. Alternatively upfront resection with or without postoperative chemotherapy might be applied, particularly in metachronous, small and single liver metastasis.\cite{10}.

Although intensification of perioperative treatment with antibodies has shown feasibility in single arm phase II trials (e.g., for bevacizumab), recently reported preliminary results of the New EPOC trial, evaluating chemotherapy and cetuximab in the perioperative setting, have raised strong scepticism\cite{49,50}. Therefore, FOLFOX currently remains the standard treatment for clearly resectable liver metastases.

Patients with unresectable disease (ESMO groups 1, 2 or 3) should receive upfront systemic chemotherapy, apart from the small group of asymptomatic patients with low tumour burden eligible for and complying with a watch and wait approach\cite{51,52}. Whereas groups 1 and 2 patients urge for intensive upfront chemotherapy to either ensure secondary resectability or allow for rapid symptom control, group 3 could be treated with a sequential treatment approach, starting with a low toxic single agent or two-drug combination regimen. Patients with asymptomatic, but surely unresectable disease due to location or overall extent and without relevant co-morbidity may not be ideally stratified in ESMO group 3, but rather treated with upfront intensive chemotherapy. Moreover, current available phase III trials included patients irrespective of ESMO grouping, thus limiting the potential prognostic or predictive value of upfront patient stratification. Although grouping patients might be helpful for guidance of treatment strategy beyond induction treatment, e.g., secondary resection, main systemic treatment options are either intensive three to four drug regimens or “sequential” one to two drugs regimens (Table 3).

**SELECTION OF AN INTENSIVE FIRST LINE REGIMEN FOR MCRC**

With respect to the increasing awareness of secondary surgery and developments in surgical and locally ablative measures, there is a growing group of patients that might
Table 3: Available treatment regimens for first-line metastatic colorectal cancer

| Treatment intensity | Molecular factor | Regimens                                      |
|---------------------|------------------|-----------------------------------------------|
| Single-agent        | 5FU/LV           | Capacitab                                     |
| Two-drug            | Capcitab/Bevacizum| FOLFOX/XELOX                                  |
| Three-drug          | RAS wt           | FOLFOX + panitumumab                          |
|                     | RAS wt           | FOLFOX + panitumumab + Bevacizum              |
|                     | RAS wt           | FOLFOX + panitumumab + Bevacizum + Panitumum  |
| Four-drug           | RAS wt           | FOLFOXIRI                                      |
|                     | RAS wt           | FOLFOXIRI + Bevacizum                         |

Combination chemotherapy with 5-fluorouracil, folinic acid (5FU/LV), and oxaliplatin (FOLFOX), or irinotecan (FOLFIRI) or both (FOLFOXIRI), or capcitabine and oxaliplatin (XELOX) or irinotecan (XELIRI).

be converted to resectability or at least achieve a “no evidence of disease” status after integration of other ablative techniques, and thus benefit from intensive upfront treatment. Therefore, either a chemotherapy doublet in combination with the VEGF antibody (bevacizumab) or an EGFR antibody [only R-45I wild-type patients], or a chemo triplet (FOLFOXIRI) and more recently the highly active four drug regimen [FOLFOXIRI and bevacizumab or similar combinations (e.g., FOLFIRI-NOX with a 5FU Bolus and slightly different doses) with EGFR antibodies] are available treatment options in this situation.

Preliminary data of the phase III PEAK study comparing FOLFOX in combination with either panitumumab or bevacizumab in 285 previously untreated, KR-45I wild-type mCRC patients indicated similar overall response rate (ORR) in the four drug regimen (89). In the all R-45I wildtype (KR-45I/ NR-45I exon 2, 3 and 4) population panitumumab and FOLFOX significantly prolonged PFS (13.1 mo vs 9.5 mo, HR = 0.63; 95%CI: 0.43-0.94, P = 0.02) and showed a favourable trend in OS (HR = 0.55; P = 0.06) compared to bevacizumab and FOLFOX. Similarly, early results from the phase III AIO KRK-0306 (FIRE 3) study comparing FOLFOXIRI with either bevacizumab or cetuximab in 592 KR-45I wildtype patients demonstrated a significantly prolonged OS (28.7 mo vs 25 mo, HR = 0.77; 95%CI: 0.62-0.96, P = 0.017) besides similar ORR (62% vs 58%, P = 0.183) and PFS (10 mo vs 10.3 mo, HR = 1.06; 95%CI: 0.88-1.26, P = 0.547) for cetuximab vs bevacizumab based chemotherapy, respectively. Recent analyses demonstrated a pronounced OS benefit in R-45I wildtype patients (33.1 mo vs 25.9 mo, P = 0.01) in favour of the cetuximab combination. Subsequent treatments were balanced in regard of use of second line oxaliplatin and the cross over to the other antibody (46.6% receiving bevacizumab after cetuximab and 41.4% receiving EGFR antibody after bevacizumab). Interestingly, treatment in the cetuximab arm was shorter with a median duration of 4.8 mo vs 5.3 mo for all drugs and 6.8 mo vs 8 mo for any drug compared to the bevacizumab arm respectively. Although the primary endpoint of the FIRE 3 trial (ORR) was not reached and results of both trials are not fully published, the similar trend in the FIRE 3 and the PEAK study suggest a beneficial impact for EGFR antibodies and chemotheraphy in first line R-45I wildtype mCRC. Further data will soon be available from the large Intergroup trial (CALGB/SWOG 80405). Feasibility and efficacy of a maximum intensive treatment with a four-drug regimen has been preliminarily shown in the phase III TRIBE trial comparing FOLFOXIRI/bevacizumab and FOLFIRIIRI/bevacizumab. Overall response rate 53% vs 65% (P = 0.006), PFS 9.7 mo vs 12.1 mo (HR = 0.75; 95%CI: 0.62-0.90, P = 0.003) and OS 25.8 mo vs 31.0 mo (HR = 0.79; 95%CI: 0.63-1.00, P = 0.054) favoured the FOLFOXIRI and bevacizumab arm. Secondary surgery was applied at similar rates in both arms (12% vs 15% with the four-drug regimen). Treatment was generally well tolerated. Although rates of distinct grade 3/4 toxicity, particular, diarrhoea (11% vs 19%), stomatitis (4% vs 9%) and neutropenia (20% vs 50%) were significantly higher with the four-drug regimen, rates of febrile neutropenia, severe adverse events and treatment related death were similar. Efficacy of FOLFOXIRI and bevacizumab was independent of KR-45I mutational status. Interestingly, patients with BRAF mutations seem to have better outcome with the four-drug regimen, despite their poor prognosis. In regard of similar outcomes in non-randomized phase II trials FOLFOXIRI/bevacizumab should be considered for BRAF mutated patients.

According to the most recently presented preliminary trial results, the choice of first line regimen, e.g., FOLFIRI + cetuximab (or FOLFOX + panitumumab) for R-45I wildtype patients or FOLFOXIRI + bevacizumab for patients with good performance status seems to be relevant for the achievement of an OS of about 2.5 years. Available treatment options are summarized in Table 4.

**SELECTION OF A NON-INTENSE OR SEQUENTIAL TREATMENT APPROACH FOR MCRC**

An increasingly ageing population with related co-morbidity which might not be amenable for a secondary curative approach (ESMO group 3) urge for comprehensive assessments focusing on toxicity and outcome prediction and well tolerated regimens for these patients (e.g., single agent or two drug combinations). In the recently reported phase III AVEX trial the addition of bevacizumab to capcitabine prolonged PFS from 5.1 to 9.1 mo (HR = 0.53; 95%CI: 0.41-0.69, P < 0.0001) and showed a strong trend in OS with an acceptable tolerability profile in patients with at least 70 years of age. Alternatively, upfront combination with fluoropyrimidines and oxaliplatin seems to be feasible in elderly patients and prefer-
Table 4  Efficacy and tolerability of three to four drug first line regimen

| Regimen                        | Efficacy | Tolerability |
|--------------------------------|----------|--------------|
|                               | PFS      | OS           | Grade 3/4 AE | SAE | Fatal AEs |
| FOLFOX + panitumumab[29]       | 10.1     | 7.3          | 25.8         | 15.5 | 84%        | 40% | 5% |
| FOLFIRI + cetuximab[34,35]     | 10.5     | NR           | 33.1         | NR  | 97% - 79%  | 26% | NR |
| FOLFOXIRI + bevacizumab[57]    | 9.9 (KRAS exon 2) | 23.5 (KRAS exon 2) | 9.4          | 21.3 | 80%        | NR  | 2% |
|                                | 10.4     | NR           | 25.9         | NR  | NR         | 20% | 3.5% |
|                                | 9.7      | NR           | 25.8         | NR  | NR         | 20% | 2.8% |
|                                | 12.1     | NR           | 31.0         | NR  | NR         | 20% | 2.8% |

These fields only informative (epidermal growth factor receptor antibodies not licensed for RAS mutated tumours). Combination chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX), or irinotecan (FOLFIRI) or both (FOLFOXIRI), or capecitabine and oxaliplatin (XELOX). PFS: Progression free survival; OS: Overall survival; AE: Adverse events; SAE: Severe adverse events; NR: Not reported.

ably, if applied with dose reductions, compared to singe agent fluoropyrimidine alone[35,36]. However, for elderly patients a tolerable and efficacious first line regimen seem to be particular relevant, with less than 50% of patients receiving second line treatment.

Sequential treatment strategies were evaluated independent of age in first line mCRC[56,68-70]. Although sequential treatment did not seem to be inferior to upfront two-drug combination in trials of the chemotherapy only era (only fluoropyrimidines, irinotecan and oxaliplatin), it is questionable whether these results can be transferred into the current treatment situation (including molecular targeting agents)[68-70].

LIMITATIONS FOR CHEMOTHERAPY AND ANTIBODY COMBINATIONS

Besides very few limitations antibodies can be combined with fluoropyrimidines, oxaliplatin and/or irinotecan in several combinations. EGFR antibodies and bevacizumab should not be combined[71,72]. If EGFR antibodies are combined with an oxaliplatin based chemotherapy backbone, infusional 5FU (FOLFOX) should be chosen instead of an oral or bolus fluoropyrimidine regimen (XELOX or FLOX) according to clinical data from the COIN and NORDIC VII studies showing no benefit for the addition of cetuximab to these regimens[72,73].

The combination of capcitabine and irinotecan (with or without oxaliplatin or bevacizumab) requires dose reductions for both drugs[74-76]. Similarly, FOLFOXIRI needs to be dose reduced in combination with EGFR antibodies[68,70].

ADDITION OF UPFRONT LOCAL TREATMENT IN UNRESECTABLE MCRC PATIENTS

Integration of secondary resection after response to induction chemotherapy is a well-established treatment approach[8,77]. The randomized CLOCC trial furthermore showed that upfront local ablation by radiofrequency with or without liver surgery followed by chemotherapy in patients with unresectable liver metastases was beneficial in terms of PFS (16.8 mo vs 9.9 mo, P = 0.025) compared to chemotherapy alone[78]. Comparative data comparing upfront with post-induction local ablation are not available. However, post-induction ablation likely offers a more stratified approach adapting for the individual patient and tumour biology and might thus be preferred.

CONCLUSION

Treatment of mCRC is complex and highly individualized taking into account disease and patient characteristics, molecular and biochemical markers and thus enabling a personalized management in terms of selecting the most appropriate measures and sequences of systemic and local treatment.

In regard of the current data unresectable patients with R-AS Wildtype should receive an EGFR antibody based chemotherapy, whereas patients with R-AS mutation should receive two or three drug chemotherapy in combination with bevacizumab, if an intensive treatment approach is chosen. For patients with a non-intense or sequential approach fluoropyrimidine and bevacizumab seems to be an efficacious and low toxic treatment option.

Future research might help to further tailor anti EGFR treatment, excluding patients deriving no benefit from EGFR inhibition. Moreover, close meshed and timely information (e.g., acquired by liquid biopsies) about the current molecular tumour situation and potentially developing resistance might be helpful to guide treatment during the course of disease.

REFERENCES

1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2 Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012; 23: 1044-1052 [PMID: 22373539 DOI: 10.1093/annonc/mds024]
3 Stintzing S, Fischer von Weikerthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V. FOLFI R plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AI0 study KRK-0306. Ann Oncol 2012; 23: 1693-1699 [PMID: 22219013]

4 Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Ascini S, Shenckopf I, Maurel J, Cunningham D, Di Costanzo F, Glimelius B, Thompson LC, Wasan HS, Middleton G, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, 2012; 57x676 4 12 7 5 3 68x781 Stein A, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone Price TJ and meta-analysis. prognostic factor for colorectal cancer: a systematic review [PMID: 10.1093/annonc/mds236]

5 Guidelines for management of patients with colon and rectal cancer. American Society for Clinical Oncology (ASCO). American Society for Colon and Rectal Surgery (ASCRS). American Society for Gastrointestinal Endoscopy (ASGE). American Society for Immunotherapy of Cancer (ASITC). American Society for Therapeutic Radiology and Oncology (ASTRO). American Society of Clinical Oncology (ASCO). 

6 Douillard JY, Siena S, Cassidy J, Tabernero J, Burke S, 2010; 2008; 2010; 2011; 2012; 22x810479 and anti-angiogenic agents. [PMID: 10.1093/jnci/djq035]

7 Falcione A, Masi G. FOLOXIRI/ bevazcimab (bev) versus FOLFOX/ bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. J Clin Oncol 2013; 31(Suppl): 3505 [abstract]

8 Folprecht G, Greumenger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoelemaecker J, Weitz J, Konopke R, Strosczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47 [PMID: 19942475 DOI: 10.1016/S1470-2045(09)70036-4]

9 Morris EJ, Yardley L, Cottier B, Poston G. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110-1118 [PMID: 20632280 DOI: 10.1002/bjs.7032]

10 Schmoll HJ, Van Cutsem E, Stein A, Valenti V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regulu J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Seboero A, Tabernero J, Aderka D, Barrosso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Plei-Kou S, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516 [PMID: 23012255 DOI: 10.1093/annonc/mds296]

11 Ren J, Li G, Ge J, Xi L, Zhou Y. ls K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2012; 55: 913-923 [PMID: 22810479]

12 Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From The Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011; 29: 2675-2682 [PMID: 21646616 DOI: 10.1200/JCO.2010.34.5520]

13 Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Michiel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317 [PMID: 11886010]

14 Sorbye H, Köhne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18: 1666-1672 [PMID: 17660495 DOI: 10.1093/annonc/mdn267]

15 Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewer AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377: 1749-1759 [PMID: 21570111 DOI: 10.1016/S0140-6736(11)60399-1]

16 Ashgar U, Hawkes E and Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010; 9: 274-281 [PMID: 21208841 DOI: 10.3816/CCC.2010.n.040]

17 Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221 [PMID: 18591556 DOI: 10.1200/JCO.2007.15.8923]

18 Karapetis CS, Khambata-Ford S, Jonker D, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalberg JR. K-Ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa084385]

19 Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18536791 DOI: 10.1200/JCO.2008.17.1437]

20 De Roock W, Jonker DJ, Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalberg JR, Simes J, Karapetis CS, Bardelli A, Tejpur S. Association of KRAS p.G13D mutation with outcome in patients with metastatic colorectal cancer. Lancet Oncol 2010; 11: 1381-1387 [PMID: 20718372 DOI: 10.1016/S1470-2045(10)70103-9]

21 Tejpur S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumour mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577 [PMID: 22734028 DOI: 10.1200/JCO.2012.42.2592]

22 Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Ge J, Li X, Idziasczczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Janss B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60813-2]

23 Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K,
Williams R, Wizorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumab. *J Clin Oncol* 2013; 31: 759-765 [PMID: 23182965 DOI: 10.1200/JCO.2012.41.1490]

24 Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O’Callaghan A, Bendstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PIECOOKO): a prospectively stratified randomised trial. *Lancet Oncol* 2013; 14: 749-759 [PMID: 23728581 DOI: 10.1016/S1470-2045(13)70163-3]

25 Douillard JY, Oliner KS, Siena S, Tabernero J, Burke R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruffi P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wieorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoai1305275]

26 De Roock W, Claes B, Bernasondi C, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Koutoula V, Papamichail D, Laurent-Puig P, Penalva-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martinis M, Bardelli A, Siena S, Santore-Bianchi A, Tabernero J, Macarrulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pleiffer P, Qvertrup C, Hansel TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Teijpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; 11: 753-762 [PMID: 20619793 DOI: 10.1016/S1470-2045(10)70130-3]

27 Di Nicolantonio F, Martini M, Molinari F, Santore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008; 26: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]

28 Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Lancet Oncol* 2013; 14: 311-320 [PMID: 23691306 DOI: 10.1016/S1470-2045(13)70163-3]

29 Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan H, Jiang J, Loupakis F, Salvatore L, Cremolini C. A randomised phase III trial of infusional fluorouracil, irinotecan, and bevacizumab as first-line treatment for metastatic colorectal cancer (PICCOLO): a prospectively stratified randomised trial. *J Clin Oncol* 2012; 30: 1466-1475 [PMID: 22446022 DOI: 10.1200/JCO.2011.39.5814]

30 Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. *Ann Oncol* 2012; 23: 1207-1213 [PMID: 21926398 DOI: 10.1093/annonc/mdt387]

31 Sadanandam A, Lyssiotis CA, Homiczko K, Colisson EA, Gibb WJ, Wullschlegler S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Uerknitt B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. *Nat Med* 2013; 19: 619-625 [PMID: 23584089 DOI: 10.1038/nm.3175]

32 Popovici V, Budinska E, Teijpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. *J Clin Oncol* 2012; 30: 1288-1295 [PMID: 22393059 DOI: 10.1200/JCO.2011.39.5814]

33 Ebert MP, Tänzer M, Balluff B, Bürgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Röcken C, Keller G, Langer R, Specht K, Porsch R, Stöhlker-Williams J, Schuster T, Ströbel P, Schmid RM. TFAPIP2-DK4 and chemoresistance in colorectal cancer. *N Engl J Med* 2013; 368: 44-53 [PMID: 22126841 DOI: 10.1056/NEJMoa1009473]

34 Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskovski S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shrik J, Stebbing J, Lenz HJ. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. *Pharmacogenomics* 2013; 13: 173-180 [PMID: ]
metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860]

Loupakis F, Cremlini C, Masti G. FOLFIRI plus bevaci-
izu mab (bev) versus FOLFI R plus bev as first-line treatment of metastatic colorectal cancer (MCRC). Results of the phase III randomized TRIBE trial [abstract]. J Clin Oncol 2013; 30 suppl: 336

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichiniser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxali-
platin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054]

Assenat E, Desseigne F, Thzenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 2011; 16: 1557-1564 [PMID: 22016477 DOI: 10.1634/theoncologist.2011-0141]

Garuti C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vrenarucci G, Mottolese M, Spederti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluoro-
uracil, leucovorin and oxaliplatin as neoadjuvant chemo-
otherapy in colorectal liver metastases: POTCHER trial. Br J Cancer 2010; 103: 1542-1547 [PMID: 20959822 DOI: 10.1038/ sbjc.6605940]

Fornaro I, Lonardi S, Masti G, Loupakis F, Bergamo F, Sal-
vatore L, Cremlini C, Schirripa M, Vivaldi C, Apri
gile G, Zeniboni A, Bracarda S, Fontanini G, Sensi E, Luchi C, Morvillo M, Zagonel V, Falcone A. FOLFIRI in combination with panitumumab as first-line treatment in quadruplple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24: 2062-2067 [PMID: 23666916 DOI: 10.1093/annonc/mdt165]

Schwartzberg L, Rivera-Herreros F, Karthaus M. A Randomized Phase 2 Study of mFOLFOX6 With Either Panitu-
mumab or Bevacizumab as 1st-line Treatment in Patients With Unresectable Wild-type KRAS Metastatic Colorectal Cancer (mCRC) [abstract]. J Clin Oncol 2013; 30 suppl: 446

Schwartzberg L, Rivera-Herreros F, Karthaus M. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevaci-
izu mab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31 suppl: 19631 [abstract]

Stintzing S, Jung A, Rossius L. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Available from: URL: http://eccamsterdam2013.ecco-org.eu/Scientific-
Programme/Searchable-Programme.aspx#anchor545

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremlini C, Cupini S, Carlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852 [PMID: 20702138 DOI: 10.1016/ S1470-2045(10)70175-3]

Loupakis F, Cremlini C, Salvatore L, Masti G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Anto-
niotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. FOLFIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63

Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-
Ly V, Cretin J, Locher C, Bouché O, BreschYs G, Charnce
J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T,
Mitry E. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31: 1464-1470 [PMID: 23460711 DOI: 10.1200/JCO.2012.42.9894]

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085 [PMID: 24028813 DOI: 10.1016/S1470-2045(13)70154-2]

Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091 [PMID: 16943526 DOI: 10.1200/JCO.2006.06.9039]

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenberg CJ, Vreugdenhil G, Loosveld OJ, van Bochoven A, Sinnige HA, Creemers GJ, Tessaelaar ME, Snee PH, Werter MJ, Møl L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142 [PMID: 17630036 DOI: 10.1016/S0140-6736(07)61086-1]

Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS2): a randomised controlled trial. Lancet 2007; 370: 143-152 [PMID: 17630037 DOI: 10.1016/S0140-6736(07)61087-3]

Cunningham D, Sirohi B, Pluzanska A, Utracka B, Saunders MP, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsi E, Birkenmeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen P. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]

Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens B, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus cetuximab or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19: 920-926 [PMID: 18065406]

Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvis M, Viudez A, Ramirez N, Bitarte N, Chopitea A, García-Foncillas J, Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010; 102: 987-994 [PMID: 20216541 DOI: 10.1038/jbc.6605595]

Ducrux M, Adenis A, Pignon JP, François E, Chauvet F, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T. Efficacy and safety of bevacizumab combination chemotherapy in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236-1245 [PMID: 23532604 DOI: 10.1016/j.ejca.2012.12.011]

Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu X, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938 [PMID: 23569301 DOI: 10.1200/JCO.2012.44.8308]

Ruers T, Punt C, Van Cooijlen F, Pieire JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23: 2619-2626 [PMID: 2245703 DOI: 10.1093/annonc/mds053]

P-Reviewers: Crea F, Ji JF, Triantafyllou K S-Editor: Guo SX L-Editor: A E-Editor: Wu HL
